Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Esperite (voorheen Cryo Save)   /   NEWS : Esperite upgrade Tranquility

Esperite (voorheen Cryo Save)« Terug naar discussie overzicht

NEWS : Esperite upgrade Tranquility

Volgen
257 Posts
Pagina: «« 1 ... 5 6 7 8 9 ... 13 »» | Laatste | Omlaag ↓
  2. flosz 19 mei 2015 20:13
    The thing that differentiates us from all the other companies is that we are devoted to developing an in vitro diagnostic product and selling it to other laboratories so that they can perform the test themselves,” Premaitha’s chief executive, Stephen Little, tells EP Vantage.

    Iona can determine the risk of a foetus having trisomies 13, 18 and 21 – Patau, Edwards’ and Down’s syndrome respectively. This is not as wide as some of the other tests in this space, but the UK group can use its CE mark as a selling point. Iona is the only test to have sought approval of European regulators; its receipt of this might persuade doctors and payers that it is the most reliable.

    www.epvantage.com/Universal/View.aspx...

    ##############

    In Europa zijn meer dan 70 keuringsinstanties actief die medische hulpmiddelen mogen certificeren met een CE-markering. Wie eenmaal een CE-certificaat heeft bemachtigd, mag ongeacht waar de keuring heeft plaatsgevonden, zijn product in alle EU-landen verkopen. Ook in Nederland.

    Het is volstrekt duidelijk dat CE-certificering onvoldoende is voor medische hulpmiddelen en apparaten.
    Dit bleek oa uit de uitzending van Zembla 16 maart 2012.
    CE-certificering vindt immers plaats door de fabrikant zelf! en betekent niets ten aanzien van kwaliteit of veiligheid bv mbt kunstheupen, knie-protheses.

    zembla.vara.nl/seizoenen/2014/aflever...
  11. Vitavita 20 mei 2015 14:12
    Beste Traders (daytraders, swingtraders etc.)onder ons bij deze een eigen draadje voor jullie aangemaakt, te weten Traders Talk.

    Graag geen berichten plaatsen onder specifieke onderwerpen, die eigenlijk gericht zijn op een bepaald product, dienst, organisatieonderdeel of berichtgeving.

    Dit om de draadjes enigszins zuiver te houden.
  13. Vitavita 23 mei 2015 22:54
    Marktpotentieel voor Tranquility:

    Biotech firm's IONA Test 'could net billions'
    By Nick Jackson - Deputy Editor, North West
    www.thebusinessdesk.com/northwest/new...

    BIOTECH firm Premaitha Health is on the verge of tapping into a multi-billion pound market with its ground breaking non-invasive prenatal screening test for pregnant women.

    Chief executive of the Manchester-based company, Dr Stephen Little, told TheBusinessDesk.com there was already strong demand for the newly-developed IONA test, which detects the risk of Downes Syndrome and other serious genetic diseases in unborn babies.

    Little launched the company in 2013, after his previous company DxS was sold to QIAGEN BV in 2009 for £85m. He was free to invested in the development of the IONA test.

    “We weren’t making money, but we were developing a product,” he said. “Now it’s there and available. We’re using it. Tests are getting done.
    This is only in the last couple of months, but it’s all happening now.

    “Up until the back end of last year, we were effectively a development company. Now we are a sales and marketing company.”

    Meanwhile, Little’s company based at Manchester Science Park, is having to fight off defence and lodge a counter claim in the High Court for alleged infringement of patents from US company Illumina and its subsidiary Verinata Health over the IONA.

    But Little, who employs 40 people at Premaitha, is unfazed by impending legal battle.

    “They’re doing the same sort of thing as us,” he said. “These methods have been around for quite a long time and I’m sure they would like to own them.

    “We’re ahead of them – we’ve got a product to market and they haven’t. We’ve got a lot of traction. They’ve got a test in America, but in terms of Europe, we’re leading the charge.

    “So if you were a great big American corporation and there was a small British company that was beating you in the market and you had some IP (intellectual property) that you could maybe use, that’s what you would do. It was no surprise because they are an aggressive company.”

    No surprise either, because the new test promises 99.9% accuracy, unlike the existing test currently available to all pregnant women, as Little explained.

    “It’s performance figures are about 90% detection and about 5% false positive,” he said. “90% detection means that for every 10 Downes babies you’ll miss one.

    “The 5% false positive rate means that for every 25 women who the test says are at risk, one of them is really at risk and 24 of them have been falsely identified by the test.

    “All 25 of those women are told you’re at high risk. So we say you’d better go off for amniocentesis. The mothers and the fathers don’t like it. It’s a needle in the stomach there’s a risk to the fetus. I don’t want to scare people, but it’s not nothing – about 1%. And there is a risk of spontaneous termination after procedure.

    “There is a big demand for the IONA screening test because the accuracy of the current screening test isn’t good enough.

    “The benefit IONA test is that its detection rate is about 99.9% and its false positive rate is less than 0.1%. To be honest, we’ve had not false positives and no false negatives so far, but there will be some in there.

    “It means that when we tell woman she’s at high risk, she really is at high risk.

    “It’s not a perfect screening test, but it’s so much better than what’s gone on before.

    “Not surprisingly, there is a huge demand for the test. It’s reckoned the market will be somewhere between $4 and $8bn in a few years’ time.”

  14. [verwijderd] 24 mei 2015 16:20
    quote:

    Vitavita schreef op 23 mei 2015 22:54:

    Marktpotentieel voor Tranquility:

    Biotech firm's IONA Test 'could net billions'
    By Nick Jackson - Deputy Editor, North West
    www.thebusinessdesk.com/northwest/new...

    BIOTECH firm Premaitha Health is on the verge of tapping into a multi-billion pound market with its ground breaking non-invasive prenatal screening test for pregnant women.

    Chief executive of the Manchester-based company, Dr Stephen Little, told TheBusinessDesk.com there was already strong demand for the newly-developed IONA test, which detects the risk of Downes Syndrome and other serious genetic diseases in unborn babies.

    Little launched the company in 2013, after his previous company DxS was sold to QIAGEN BV in 2009 for £85m. He was free to invested in the development of the IONA test.

    “We weren’t making money, but we were developing a product,” he said. “Now it’s there and available. We’re using it. Tests are getting done.
    This is only in the last couple of months, but it’s all happening now.

    “Up until the back end of last year, we were effectively a development company. Now we are a sales and marketing company.”

    Meanwhile, Little’s company based at Manchester Science Park, is having to fight off defence and lodge a counter claim in the High Court for alleged infringement of patents from US company Illumina and its subsidiary Verinata Health over the IONA.

    But Little, who employs 40 people at Premaitha, is unfazed by impending legal battle.

    “They’re doing the same sort of thing as us,” he said. “These methods have been around for quite a long time and I’m sure they would like to own them.

    “We’re ahead of them – we’ve got a product to market and they haven’t. We’ve got a lot of traction. They’ve got a test in America, but in terms of Europe, we’re leading the charge.

    “So if you were a great big American corporation and there was a small British company that was beating you in the market and you had some IP (intellectual property) that you could maybe use, that’s what you would do. It was no surprise because they are an aggressive company.”

    No surprise either, because the new test promises 99.9% accuracy, unlike the existing test currently available to all pregnant women, as Little explained.

    “It’s performance figures are about 90% detection and about 5% false positive,” he said. “90% detection means that for every 10 Downes babies you’ll miss one.

    “The 5% false positive rate means that for every 25 women who the test says are at risk, one of them is really at risk and 24 of them have been falsely identified by the test.

    “All 25 of those women are told you’re at high risk. So we say you’d better go off for amniocentesis. The mothers and the fathers don’t like it. It’s a needle in the stomach there’s a risk to the fetus. I don’t want to scare people, but it’s not nothing – about 1%. And there is a risk of spontaneous termination after procedure.

    “There is a big demand for the IONA screening test because the accuracy of the current screening test isn’t good enough.

    “The benefit IONA test is that its detection rate is about 99.9% and its false positive rate is less than 0.1%. To be honest, we’ve had not false positives and no false negatives so far, but there will be some in there.

    “It means that when we tell woman she’s at high risk, she really is at high risk.

    “It’s not a perfect screening test, but it’s so much better than what’s gone on before.

    “Not surprisingly, there is a huge demand for the test. It’s reckoned the market will be somewhere between $4 and $8bn in a few years’ time.”

    Nu vertaald in Jip & Janneke taal. Heeft dit positief effect op de koers?

  16. forum rang 10 DeZwarteRidder 24 mei 2015 17:08
    De concurrentie is moordend:

    Meanwhile, Little’s company based at Manchester Science Park, is having to fight off defence and lodge a counter claim in the High Court for alleged infringement of patents from US company Illumina and its subsidiary Verinata Health over the IONA.

    But Little, who employs 40 people at Premaitha, is unfazed by impending legal battle.

    “They’re doing the same sort of thing as us,” he said. “These methods have been around for quite a long time and I’m sure they would like to own them.

    “We’re ahead of them – we’ve got a product to market and they haven’t. We’ve got a lot of traction. They’ve got a test in America, but in terms of Europe, we’re leading the charge.

    “So if you were a great big American corporation and there was a small British company that was beating you in the market and you had some IP (intellectual property) that you could maybe use, that’s what you would do. It was no surprise because they are an aggressive company.”
  18. forum rang 8 aextracker 25 mei 2015 08:32
    quote:

    DeZwarteRidder schreef op 24 mei 2015 17:04:

    [...]
    Nee, negatief, de concurrentie is gewoon slimmer dan Esperite.
    Gevalletje van "reputatie management" ?

    Aparte conclusie wanneer je bedenkt, dat Esperite en diens UK partner de US company e.a. concurrenten waar een gereferreed wordt "te snel af zijn geweest" met de leadtime to market in wat "een nieuwe markt wordt genoemd".

    Op welk punt is de concurrentie slimmer dan Esperite ?

    Tracker
  19. forum rang 10 DeZwarteRidder 25 mei 2015 09:12
    quote:

    aextracker schreef op 25 mei 2015 08:32:

    [...]Gevalletje van "reputatie management" ?
    Aparte conclusie wanneer je bedenkt, dat Esperite en diens UK partner de US company e.a. concurrenten waar een gereferreed wordt "te snel af zijn geweest" met de leadtime to market in wat "een nieuwe markt wordt genoemd".
    Op welk punt is de concurrentie slimmer dan Esperite ?
    Tracker
    De IONA-test lijkt een stuk beter te werken dan de test die Esperite mag verkopen.
257 Posts
Pagina: «« 1 ... 5 6 7 8 9 ... 13 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
Accsys 0,572 +0,02 +2,88%
Pharming 0,893 +0,02 +2,23%
AZERION 1,100 +0,02 +1,85%
AMG Critical Materials N.V. 13,840 +0,23 +1,69%
Sligro 11,040 +0,18 +1,66%
IMCD 141,500 +2,30 +1,65%
Vopak 42,840 +0,68 +1,61%
Basic-Fit 22,000 +0,34 +1,57%
HEIJMANS KON 31,250 +0,45 +1,46%
TomTom 4,974 +0,07 +1,43%
AALBERTS NV 34,180 +0,48 +1,42%
Fugro 16,510 +0,23 +1,41%
ASMI 570,000 +7,20 +1,28%
RANDSTAD NV 40,050 +0,49 +1,24%
Eurocommercial Properties 22,450 +0,25 +1,13%
BAM 4,216 +0,05 +1,10%
ADYEN NV 1.435,600 +15,60 +1,10%
BESI 134,950 +1,45 +1,09%
NX FILTRATION 3,325 +0,04 +1,06%
RENEWI 9,680 +0,10 +1,04%
SBM Offshore 16,880 +0,17 +1,02%
SHELL PLC 29,545 +0,28 +0,94%
ALLFUNDS GROUP 5,085 +0,04 +0,89%
ASCX 1.248,39 +11,03 +0,89%
JDE PEET'S 16,420 +0,14 +0,86%
Arcadis 58,950 +0,50 +0,86%
Avantium 1,774 +0,01 +0,80%
Kendrion 10,160 +0,08 +0,79%
Akzo Nobel 56,180 +0,44 +0,79%
ACOMO 17,220 +0,12 +0,70%
ASML 688,500 +4,70 +0,69%
Philips Koninklijke 24,490 +0,16 +0,66%
THEON INTERNAT 12,580 +0,08 +0,64%
ArcelorMittal 22,270 +0,14 +0,63%
Galapagos 25,920 +0,16 +0,62%
ING 14,834 +0,09 +0,58%
Brunel 8,760 +0,05 +0,57%
AMX 832,53 +4,67 +0,56%
Aperam 25,000 +0,14 +0,56%
DSM FIRMENICH AG 97,940 +0,52 +0,53%
ABN AMRO BANK N.V. 14,640 +0,08 +0,51%
SIGNIFY NV 21,060 +0,10 +0,48%
AEX 876,26 +4,04 +0,46%
UNILEVER PLC 55,020 +0,24 +0,44%
WDP 18,870 +0,07 +0,37%
KPN 3,506 +0,01 +0,37%
Nedap N.V. 54,200 +0,20 +0,37%
INPOST 16,360 +0,06 +0,37%
NN Group 41,610 +0,14 +0,34%
Heineken 68,460 +0,22 +0,32%
NSI 18,940 +0,06 +0,32%
Air France-KLM 8,110 +0,02 +0,30%
Ahold Delhaize 31,240 +0,09 +0,29%
UMG 24,560 +0,05 +0,20%
Sif Holding 12,160 +0,02 +0,16%
Wereldhave 13,740 +0,02 +0,15%
ASR Nederland 44,670 +0,06 +0,13%
Van Lanschot Kempen NV 42,800 +0,05 +0,12%
OCI 10,905 +0,01 +0,09%
RELX 43,460 +0,02 +0,05%
CM.COM 5,510 0,00 0,00%
PostNL 1,030 0,00 0,00%
Wolters Kluwer 159,500 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
Fagron 16,700 -0,18 -1,07%
PROSUS 38,900 -0,38 -0,98%
CTP 14,780 -0,12 -0,81%
JUST EAT TAKEAWAY 13,755 -0,08 -0,58%
FASTNED 21,150 -0,10 -0,47%
Vastned 21,500 -0,10 -0,46%
ForFarmers 3,405 -0,02 -0,44%
EBUSCO HOLDING 1,090 0,00 -0,38%
Corbion 21,400 -0,08 -0,37%
B&S Group SA 4,315 -0,01 -0,35%
Aegon 5,608 -0,01 -0,18%
Alfen N.V. 11,370 -0,02 -0,18%
Flow Traders 21,460 -0,02 -0,09%
TKH 33,160 -0,02 -0,06%
EXOR NV 88,000 -0,05 -0,06%
vlag naam koers verschil relatief verschil
AEX 876,26 +4,04 +0,46%
AEX GR 3.436,98 +15,85 +0,46%
Germany40^ 19.893,70 +8,95 +0,05%
FTSE 100 8.136,99 +34,27 +0,42%
EURO50 4.877,71 0,00 0,00%
US30^ 42.908,80 0,00 0,00%
Nasd100^ 21.487,90 0,00 0,00%
US500^ 5.972,84 0,00 0,00%
Japan225^ 39.312,70 0,00 0,00%
VD-NEW 15,69 -0,15 -0,98%
#/^ Index indications calculated real time, zie disclaimer